Vaxil Bio Ltd. (TSXV: VXL)
Health Care · Biotechnology · CA
CA$0.16
-8.57% today · 0.0% 1Y
Vaxil Bio Ltd. (TSXV: VXL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $458.88K and employs 3 people.
Over the last twelve months the share price has gained 0.0%, trading between 0.13 and 0.29.
Tweenvest scores Vaxil Bio Ltd. across four factors: quality 30/100. Its strongest factor is quality.
VXL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $458.88K
- Revenue (TTM)
- —
- P/E
- 1.04
- EPS
- 0.15
- Dividend yield
- —
- Beta (5Y)
- -0.88
- 52-week high
- CA$0.29
- 52-week low
- CA$0.13
- Avg volume (3M)
- —
- Shares outstanding
- 3.98M
- Employees
- 3
- Next earnings
- —
About Vaxil Bio Ltd.
Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.
- ISIN
- CA92243L2066
- Listed since
- Mar 30, 2010
- Exchange
- TSX Venture Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.